MARKET

VTVT

VTVT

Vtv Therapeutics
NASDAQ
1.020
+0.035
+3.57%
After Hours: 1.040 +0.02 +1.96% 16:06 10/04 EDT
OPEN
1.000
PREV CLOSE
0.9848
HIGH
1.030
LOW
0.9700
VOLUME
77.71K
TURNOVER
0
52 WEEK HIGH
1.760
52 WEEK LOW
0.3820
MARKET CAP
106.67M
P/E (TTM)
-3.7376
1D
5D
1M
3M
1Y
5Y
vTv Therapeutics (NASDAQ:VTVT shareholders incur further losses as stock declines 17% this week, taking five-year losses to 84%
vTv Therapeutics Inc. ( NASDAQ:VTVT ) shareholders should be happy to see the share price up 28% in the last quarter...
Simply Wall St. · 09/23 11:04
BRIEF-Medpace Investors Reports 5.16% Passive Stake Of Class A Common Stock In vTv Therapeutics
BRIEF-Medpace Investors Reports 5.16% Passive Stake Of Class A Common Stock In vTv Therapeutics
Reuters · 08/23 19:14
This Diabetes Drug's 'Licensing Opportunity Is Underappreciated,' Analyst Says
Benzinga · 08/19 16:42
After third leadership change in less than a year, vTv Therapeutics Inc. reports $3.2 net loss in Q2
Following another CEO transition and company restructuring, vTv Therapeutics Inc., the High Point clinical-stage pharmaceutical company, reported a net loss of $3.2 million during the second quarter of 2022.
American City Business Journals · 08/18 10:41
vTv Therapeutics GAAP EPS of -$0.04
vTv Therapeutics press release (<span class="ticke...
Seekingalpha · 08/16 07:00
BRIEF-vTv Therapeutics Reports Net Loss Of $0.04 Per Basic Share
BRIEF-vTv Therapeutics Reports Net Loss Of $0.04 Per Basic Share
Reuters · 08/15 22:30
What You Need To Know About vTv Therapeutics Inc.'s (NASDAQ:VTVT) Investor Composition
A look at the shareholders of vTv Therapeutics Inc. ( NASDAQ:VTVT ) can tell us which group is most powerful. Large...
Simply Wall St. · 08/13 12:25
Months after celebrating its first exit, CinRx invests $10M in newest portfolio company
A Cincinnati-based portfolio company that celebrated a massive exit earlier this year has invested millions to accelerate development of a new treatment option for people with Type 1 diabetes.
American City Business Journals · 08/09 10:09
More
About VTVT
vTv Therapeutics Inc. is a clinical-stage pharmaceutical company that is engaged in the discovery and development of orally administered small molecule drug candidates. Its products pipeline includes TTP399, TTP273, HPP737 and HPP593. TTP399 is an orally administered, small molecule, liver-selective glucokinase activator (GKA) in development potential oral anti-diabetic for the treatment of type I diabetes. TTP399 completed the SimpliciT-I Study, a Phase II trial in patients with type I diabetes as an add-on to insulin therapy. Its HPP737 is an orally administered, non- central nervous system (CNS) penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases. TTP273 is an orally available, small molecule glucagon-like peptide 1 (GLP-1) receptor agonist, which is focused on treating postprandial hyperglycemia in cystic fibrosis related diabetes (CFRD) patients and cystic fibrosis patients. Its products pipeline also includes Nrf2/Bach1 Modulator Program.

Webull offers kinds of vTv Therapeutics Inc stock information, including NASDAQ:VTVT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VTVT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VTVT stock methods without spending real money on the virtual paper trading platform.